Abstract
Efforts to treat transmissible spongiform encephalopathy (TSE) date back to the middle of the 20th century. Early studies were colored by the belief that TSE was caused by a ‘slow’ or ‘unconventional’ virus, and a variety of antiinfective agents, together with scores of drugs drawn at random from other categories, predictably failed to provide any benefit, apart from polyanionic compounds and polyene antibiotics that prolonged the incubation period of disease in experimental animals. With the discovery in the 1980s that TSE apparently results from the malformation of a normal host protein, attempts at treatment could at last be rationally focused, and can be broadly categorized as genetic, immunologic, and pharmacologic. Genetic ‘neutralization’ of the pathogen has shown excellent results in experimental animals but is unlikely to be useful until the same kind of engineering can be effectively applied to humans. Immunologic methods to accomplish the same result have also shown some success in animals, but forays into the pharmacologic realm have been generally disappointing. Most reported ‘successes’ have been limited to prolonged incubation periods, and even then only when the treatment was begun at or near the time of infection, which is not known in sporadic or familial human disease. However, a few methods using the more rigorous model of treatment nearer the onset of symptomatic disease have begun to yield promising results that, if coupled with a practical screening test for pre-clinical infection, would be the optimal strategy for prevention or cure.
CNS & Neurological Disorders - Drug Targets
Title: An Historical Perspective on Efforts to Treat Transmissible Spongiform Encephalopathy
Volume: 8 Issue: 5
Author(s): P. Brown
Affiliation:
Abstract: Efforts to treat transmissible spongiform encephalopathy (TSE) date back to the middle of the 20th century. Early studies were colored by the belief that TSE was caused by a ‘slow’ or ‘unconventional’ virus, and a variety of antiinfective agents, together with scores of drugs drawn at random from other categories, predictably failed to provide any benefit, apart from polyanionic compounds and polyene antibiotics that prolonged the incubation period of disease in experimental animals. With the discovery in the 1980s that TSE apparently results from the malformation of a normal host protein, attempts at treatment could at last be rationally focused, and can be broadly categorized as genetic, immunologic, and pharmacologic. Genetic ‘neutralization’ of the pathogen has shown excellent results in experimental animals but is unlikely to be useful until the same kind of engineering can be effectively applied to humans. Immunologic methods to accomplish the same result have also shown some success in animals, but forays into the pharmacologic realm have been generally disappointing. Most reported ‘successes’ have been limited to prolonged incubation periods, and even then only when the treatment was begun at or near the time of infection, which is not known in sporadic or familial human disease. However, a few methods using the more rigorous model of treatment nearer the onset of symptomatic disease have begun to yield promising results that, if coupled with a practical screening test for pre-clinical infection, would be the optimal strategy for prevention or cure.
Export Options
About this article
Cite this article as:
Brown P., An Historical Perspective on Efforts to Treat Transmissible Spongiform Encephalopathy, CNS & Neurological Disorders - Drug Targets 2009; 8 (5) . https://dx.doi.org/10.2174/187152709789541989
DOI https://dx.doi.org/10.2174/187152709789541989 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Peroxisome Proliferator-Activated Receptor (PPAR) in Metabolic Syndrome and Type 2 Diabetes Mellitus
Current Diabetes Reviews Hyperhomocysteinemia and Cardiovascular Risk: Effect of Vitamin Supplementation in Risk Reduction
Current Clinical Pharmacology Recent updates on the dynamic association between oxidative stress and neurodegenerative disorders
CNS & Neurological Disorders - Drug Targets Strain Specificity and Drug Resistance in Anti-Prion Therapy
Current Topics in Medicinal Chemistry The Therapeutic Potential of Rutin for Diabetes: An Update
Mini-Reviews in Medicinal Chemistry Rivastigmine Transdermal Patch and Physical Exercises for Alzheimer's Disease: A Randomized Clinical Trial
Current Alzheimer Research Cystatin C: An Emerging Biomarker in Cardiovascular Disease
Current Topics in Medicinal Chemistry Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise
Current Psychopharmacology Lenticulostriate Artery and Lenticulostriate-artery Neural Complex: New Concept for Intracerebral Hemorrhage
Current Pharmaceutical Design Preface
Current Enzyme Inhibition Oxidative Stress Induced Mitochondrial DNA Deletion as a Hallmark forthe Drug Development in the Context of the Cerebrovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Properties and Clinical Development of a Novel Coating Technology: The poly[bis(trifluoroethoxy)phosphazene]
Recent Patents on Drug Delivery & Formulation Targeting Stress Activated Protein Kinases, JNK and p38, as New Therapeutic Approach for Neurodegenerative Diseases
Central Nervous System Agents in Medicinal Chemistry Comparison of Machine Learning Techniques Based Brain Source Localization Using EEG Signals
Current Medical Imaging Nanotechnology Driven Approaches for the Management of Parkinson’s Disease: Current Status and Future Perspectives
Current Drug Metabolism Bipolar Spectrum Disorder: Origins and State of the Art
Current Psychiatry Reviews Is Covalently Crosslinked Aβ Responsible for Synaptotoxicity in Alzheimers Disease?
Current Alzheimer Research Preeclampsia and the Future Development of Cardiovascular Disease: A Review
Current Women`s Health Reviews Cellular Protection and Therapeutic Potential of Tocotrienols
Current Pharmaceutical Design Visual Spatial Attention Training Improve Spatial Attention and Motor Control for Unilateral Neglect Patients
CNS & Neurological Disorders - Drug Targets